STOCK TITAN

DiaMedica Therapeutics (DMAC) Stock News, Sep 2023-May 2024

DMAC NASDAQ

DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.

Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its first quarter 2024 financial results on May 8th, followed by a business update and live conference call on May 9th. The company focuses on developing recombinant KLK1 (DM199) for acute ischemic stroke treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
management
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.50%
Tags
conferences

FAQ

What is the current stock price of DiaMedica Therapeutics (DMAC)?

DiaMedica Therapeutics (DMAC) last closed at $8.38.

What is the market cap of DiaMedica Therapeutics (DMAC)?

The market cap of DiaMedica Therapeutics (DMAC) is approximately $452.2M.